Ruparel Food Products Limited (RFL)
Market Closed
26 May, 04:51
MSE MSE Primary ₹
142. 75
+4.75
+3.442%
₹
47.04M Market Cap
17.6 P/E Ratio
- Div Yield
19 Volume
0 Eps
₹ 138
Previous Close Want to track RFL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
RFL closed Tuesday higher at ₹142.75, an increase of 3.442% from Monday's close, completing a monthly decrease of -0.7647% or -₹1.1. Over the past 12 months, RFL stock gained 9.8077%.
RFL is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
RFL Chart
Ruparel Food Products Limited (RFL) FAQ
What is the stock price today?
The current price is ₹142.75.
On which exchange is it traded?
Ruparel Food Products Limited is listed on MSE.
What is its stock symbol?
The ticker symbol is RFL.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 47.04M.
Has Ruparel Food Products Limited ever had a stock split?
No, there has never been a stock split.
Ruparel Food Products Limited Profile
| Financial Services Industry | Financials Sector | Howard S. Jonas CEO | MSE Exchange | 75062E106 CUSIP |
| US Country | 23 Employees | - Last Dividend | - Last Split | 26 Mar 2018 IPO Date |
Overview
Rafael Holdings, Inc., based in Newark, New Jersey, is primarily focused on holding interests in both clinical and early-stage pharmaceutical companies, alongside commercial real estate assets in the United States and Israel. Operating since its incorporation in 2017, the company functions through two distinct segments: Healthcare and Real Estate. Its principal activities include the development and commercialization of therapeutic products that leverage the metabolic differences between normal and cancer cells. The company's strategic position allows it to contribute significantly to the oncology field through its innovative research and development initiatives.
Products and Services
- CPI-613 (Devimistat): This leading drug candidate is currently in a Phase III clinical study for treating metastatic pancreatic cancer and acute myeloid leukemia. Devimistat represents a novel approach to cancer treatment, focusing on the unique energy metabolism in cancer cells.
- Promitil: A proprietary prodrug form of mitomycin-C, this molecule is engineered for targeted delivery to cancer cells. It has completed Phase 1B clinical studies. Promitil underscores the company's commitment to developing safer and more effective cancer therapies.
- Folate-targeted Promitil (Promi-Fol): Aimed at the local treatment (intravesical) of superficial bladder cancer, Promi-Fol leverages targeted delivery technologies to improve treatment outcomes in bladder cancer. This innovation represents a specialized approach towards cancer therapy, with potential to minimize systemic side effects.
- Promi-Dox: As a highly potent dual drug liposome, Promi-Dox combines MLP and doxorubicin for the targeting of a basket of tumors. This drug is in development stages but signifies the company's efforts in offering more comprehensive cancer treatment solutions.
- Surgical and procedural devices: In addition to its pharmaceutical endeavors, Rafael Holdings is involved in the development of devices for surgical and procedural applications, including orthopedic arthroscopy instrumentation. This diversification showcases the company’s intent to contribute to different facets of healthcare beyond drug development.
Contact Information
Address: 520 Broad Street
Phone: 212 658 1450
Website: https://www.rafaelholdings.com
